| Literature DB >> 27246346 |
Julien Ferrand1, Youssef El Samad2, Benoit Brunschweiler3, Franck Grados1, Nassima Dehamchia-Rehailia1, Alice Séjourne1, Jean-Luc Schmit2, Antoine Gabrion3, Patrice Fardellone1, Julien Paccou4.
Abstract
BACKGROUND: The objective of this ambispective study was to determine outcomes and associated factors for adult patients with confirmed septic arthritis (SA).Entities:
Keywords: C-reactive protein; Clinical characteristics; Mortality; Poor functional outcome; Risk factors; Septic arthritis
Mesh:
Year: 2016 PMID: 27246346 PMCID: PMC4888402 DOI: 10.1186/s12879-016-1540-0
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Study flow chart
Characteristics of the study participants
| Variables | Number | All participants ( | Small joint involvement ( | Large joint involvement ( | p-value |
|---|---|---|---|---|---|
| Age, years | 109 | 62 [16–96] | 52.5 [16–89] | 65 [17–96] |
|
| Male gender, n (%) | 109 | 74 (67.9) | 19 (55.9) | 55 (73.3) | 0.07 |
| Body mass index (kg/m2) | 80 | 25 [14.5–48] | 24.1 [17–40.4] | 26.05 [14.5–48] | 0.25 |
| Creatinine clearance (ml/min) | 105 | 80 [5–150] | 84 [13–150] | 78 [5–150] | 0.35 |
| C-reactive protein (mg/l) | 102 | 120 [3–640] | 23 [3–230] | 166 [3–640] |
|
| Length of hospital stay (days) | 109 | 16 [2–216] | 6 [2–56] | 21 [2–216] |
|
| Duration of oral therapy (days) | 102 | 52.5 [3–112] | 42 [3–84] | 84 [10–112] |
|
| Department, n (%) | 109 | ||||
| -Rheumatology | 51 (47.8) | 5 (14.7) | 46 (61.4) | ||
| -Orthopaedics | 37 (33.9) | 28 (82.3) | 9 (12.0) | ||
| -Infectious Dis. | 20 (18.3) | 1 (3.0) | 19 (25.3) | ||
| -Geriatric Med. | 1 (<1) | 0 (<1) | 1 (1.3) |
| |
|
| 109 | 59 (59.0) | 16 (51.6) | 43 (62.3) | 0.31 |
| Diabetes, n (%) | 109 | 26 (23.8) | 4 (11.8) | 22 (29.3) |
|
| Cardiovascular disease, n (%) | 109 | 45 (41.3) | 6 (17.6) | 39 (52.0) |
|
| Cancer, n (%) | 109 | 22 (20.2) | 4 (11.8) | 18 (24.0) | 0.14 |
| Surgery, n (%) | 109 | 60 (55.0) | 26 (75.5) | 34 (45.3) |
|
| All-cause death, n (%) | 107 | 19 (17.8) | 2 (6.2) | 17 (22.7) |
|
| Death directly attributable to SA, n (%) | 107 | 6 (5.6) | 0 (<1) | 6 (8.0) | 0.10 |
| Poor functional outcome, n (%) | 88 | 28 (31.8) | 7 (23.3) | 21 (36.2) | 0.22 |
Data are reported as the median [range]. Statistically significant results are indicated in bold type
Joint sites involved with SA (109 adult patients with confirmed SA (including 11 with multiple joint involvements with a total of 130 infected joints))
| Joint involved | Number ( | Percent | Number ( | Percent |
|---|---|---|---|---|
| Small joint involvement (fingers and toes) | 34 | 31.2 | 36 | 27.7 |
| Knee | 25 | 22.9 | 31 | 23.9 |
| Shoulder (glenohumeral or acromioclavicular) | 16 | 14.7 | 20 | 15.4 |
| Hip | 12 | 11.0 | 16 | 12.3 |
| Ankle or subtalar | 9 | 8.2 | 14 | 10.8 |
| Sacroiliac | 5 | 4.6 | 5 | 3.8 |
| Symphisis pubis | 3 | 2.7 | 3 | 2.3 |
| Wrist | 2 | 1.9 | 2 | 1.5 |
| Elbow | 2 | 1.9 | 2 | 1.5 |
| Sternoclavicular | 1 | 0.9 | 1 | 0.8 |
Organisms identified as causes of SA
| Organism | Number ( |
|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Coliform bacilli |
|
|
|
|
| Other |
|
| Mixed infections |
|
| Unknown |
|
Concomitant conditions
| Concomitant conditions | Number | Percent |
|---|---|---|
| Heart disease | 37 | 33.9 |
| Current smokers | 36 | 33.0 |
| Diabetes mellitus | 26 | 23.9 |
| Osteoarthritis | 24 | 22.0 |
| Previous cancer | 22 | 20.2 |
| Peripheral arterial disease | 19 | 17.4 |
| Kidney disease | 17 | 13.8 |
| Gout/chondrocalcinosis | 15 | 13.8 |
| Alcohol abuse | 13 | 11.9 |
| Lung disease | 12 | 11.0 |
| Oral corticosteroids | 10 | 9.2 |
| Skin ulceration | 10 | 9.2 |
| Eschars | 9 | 8.2 |
| Liver disease | 7 | 6.4 |
| Rheumatoid arthritis and other inflammatory rheumatic disease | 7 | 6.4 |
| Intra-articular corticosteroids | 3 | 2.8 |
| Intravenous drug abuse | 2 | 1.8 |
Univariate analysis of factors possibly associated with mortality attributable directly to septic arthritis
| Yes ( | No ( | p-value | Odds ratio [95 % CI] | Univariate analysis | |
|---|---|---|---|---|---|
|
|
|
|
|
|
|
| Gender (Female) | 3 (50 %) | 31 (31 %) | 0.380 | 2.26 [0.40–12.80] | 0.335 |
| Knee involvement | 3 (50 %) | 22 (22 %) | 0.138 | 3.59 [0.63–20.61] | 0.133 |
| Hip involvement | 0 (<1 %) | 12 (12 %) | 1 | not defined | 0.993 |
| Multiple joint involvement | 2 (33 %) | 8 (8 %) | 0.097 | 5.81 [0.73–35.11] | 0.062 |
| Cardiovascular disease | 3 (50 %) | 42 (42 %) | 0.694 | 1.40 [0.25–7.91] | 0.686 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Previous cancer | 3 (50 %) | 19 (19 %) | 0.100 | 4.32 [0.75–24.95] | 0.087 |
|
|
|
|
|
|
|
| Time to presentation (days) | 11 [4–24] | 7 [0–120] | 0.695 | 0.98 [0.92–1.02] | 0.507 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4 (67 %) | 53 (58 %) | 1 | 1.47 [0.27–11] | 0.665 |
| Joint surgery | 1 (17 %) | 57 (56 %) | 0.091 | 0.15 [0.01–1.002] | 0.093 |
|
|
|
|
|
|
|
| Small joint involvement | 0 (<1 %) | 32 (32 %) | 0.175 |
| 0.993 |
MDRD Modification of Diet in Renal Disease
Statistically significant results are indicated in bold type
Univariate analysis of factors possibly associated with a poor functional outcome in septic arthritis
| Yes ( | No ( | p-value | Odds ratio [95 % CI] | Univariate analysis | |
|---|---|---|---|---|---|
|
| 64.0 [36–90] | 54.5 [16–95] | 0.076 |
|
|
| Gender (Female) | 10 (36 %) | 19 (32 %) | 0.707 | 1.20 [0.46–3.07] | 0.707 |
| Knee involvement | 3 (11 %) | 13 (22 %) | 0.252 | 0.43 [0.09–1.50] | 0.224 |
|
|
|
|
|
|
|
| Multiple joint involvement | 3 (11 %) | 4 (7 %) | 0.675 | 1.68 [0.31–8.17] | 0.517 |
| Small joint involvement | 7 (25 %) | 23 (38 %) | 0.219 | 0.54 [0.19–1.41] | 0.223 |
| Cardiovascular disease | 12 (43 %) | 19 (32 %) | 0.306 | 1.62 [0.64–4.10] | 0.308 |
|
|
|
|
|
|
|
| Rheumatoid arthritis and related conditions | 1 (4 %) | 3 (5 %) | 1 | 0.70 [0.03–5.79] | 0.765 |
| Previous cancer | 8 (29 %) | 7 (12 %) | 0.049 | 3.03 [0.97–9.73] | 0.056 |
| Diabetes mellitus | 7 (25 %) | 13 (22 %) | 0.728 | 1.21 [0.40–3.40] | 0.728 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C-reactive protein (mg/l) | 120 [3–342] | 105.5 [3–465] | 0.862 | 0.999 [0.995–1.004] | 0.839 |
|
| 15 (58 %) | 29 (55 %) | 0.802 | 1.13 [0.44–2.96] | 0.803 |
| Joint surgery | 17 (61 %) | 33 (55 %) | 0.614 | 1.26 [0.51–3.21] | 0.615 |
MDRD Modification of Diet in Renal Disease
Statistically significant results are indicated in bold type